Tau-Binding Antibodies Inhibit Aggregation and Promote Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical approaches for Alzheimer's disease primarily focus on symptomatic treatment and fail to address the underlying pathological processes, necessitating the development of molecules that can interfere with early stages of the disease to prevent cognitive decline and treat tauopathies effectively.
Innovation Solution
Development of novel human binding molecules, such as antibodies or antigen-binding fragments, specifically designed to bind to tau paired helical filaments (PHFs), inhibit their spreading, and mediate their uptake and degradation by microglia, offering a therapeutic and diagnostic tool for tauopathies like Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If symptomatic treatment approaches are used for Alzheimer's disease, then immediate symptom relief may be achieved, but the underlying pathological processes are not addressed and disease progression continues
Solution Approach 1:
The patent applies preliminary action by developing binding molecules that target and inhibit tau aggregation at early pathological stages, before extensive neuronal damage occurs. The molecules prevent the formation and spreading of tau seeds, addressing the underlying pathology proactively rather than treating symptoms after they manifest.
Solution Approach 2:
The binding molecules serve as intermediaries that specifically bind to tau proteins and tau aggregates, mediating their clearance by microglia. These molecules bridge the gap between the pathological tau deposits and the immune system's clearance mechanisms, enabling targeted removal of toxic aggregates without affecting normal tau function.
2Reliability
If molecules that interfere with early disease stages are developed, then prevention of cognitive decline and treatment of underlying pathology is achieved, but the complexity of drug development and targeting increases
Solution Approach 1:
The patent employs parameter changes by optimizing the binding characteristics of the molecules to achieve high specificity for pathological tau conformations. The molecules are designed with specific affinity and selectivity parameters that enable them to distinguish between aggregated and soluble tau, allowing effective intervention without requiring overly complex molecular structures.
3Reliability
If binding molecules are designed to inhibit tau aggregation and promote clearance, then therapeutic efficacy is improved, but the specificity and selectivity requirements for the molecules increase
Solution Approach 1:
The binding molecules exhibit local quality by displaying different binding affinities for different conformational states of tau. They are engineered to specifically recognize and bind to the unique structural characteristics of aggregated tau while maintaining low affinity for soluble, functional tau, enabling selective targeting of pathological deposits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These binding molecules effectively inhibit tau aggregation and promote its clearance, potentially delaying disease progression and improving treatment outcomes for Alzheimer's and other tau-related disorders.
Implementation Method 1
binding molecules, e.g. antibodies or antigen-binding fragments thereof, that specifically bind to tau
Implementation Method 2
mediating uptake and degradation of tau aggregates by microglia
Data Source
AI summary
The invention relates to binding molecules and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using the binding molecules or antigen-binding fragments.